# Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial

> **NCT06326008** · PHASE1 · RECRUITING · sponsor: **Beijing GoBroad Hospital** · enrollment: 48 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, in Relapse

## Interventions

- **DRUG:** Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy

## Key facts

- **NCT ID:** NCT06326008
- **Lead sponsor:** Beijing GoBroad Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2026-06-15
- **Final completion:** 2026-12-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06326008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06326008, "Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06326008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*